摘要
二肽基肽酶-4(DPP-4)抑制剂利格列汀(linagliptin,Tradjenta)2011年5月2日获得美国FDA批准上市,是一种具有新型作用机制的2型糖尿病(T2DM)治疗药物。临床试验结果证实,利格列汀单用或与其他抗糖尿病药物联用,均能有效降低T2DM患者的糖化血红蛋白水平、空腹血浆葡萄糖浓度和餐后2 h血浆葡萄糖浓度,对体重无明显影响,发生低血糖的风险低,肝功能下降和肾功能不全的T2DM患者无需调整给药剂量,具有较好的安全性及耐受性。
Dipeptidyl peptidase-4（DPP-4） inhibitor linagliptin（Tradjenta） is a therapeutic drug with new action mechanism for treating type 2 diabetes（T2DM）.It was approved by FDA in the US on 2nd May 2011.Clinical trial results have confirmed that linagliptin can effectively reduce glycosylated hemoglobin level,plasma glucose concentration and two-hour postprandial plasma glucose concentration as monotherapy or in combination with other antihyperglycemic agents.Linagliptin has a relatively low porpensity for hypoglycemia and does not adversely affect weight.It does not require dosage adjustments in T2DM patients with declined liver function and impaired renal function.
出处
《国际药学研究杂志》
CAS
CSCD
2013年第3期286-290,294,共6页
Journal of International Pharmaceutical Research
基金
云南省应用基础研究计划重点项目(2006C009Z)
